Thermo Fisher Scientific (NYSE:TMO) Shares Sold Off Rep. Greg Landsman

Representative Greg Landsman (D-Ohio) recently sold shares of Thermo Fisher Scientific Inc. (NYSE:TMO). In a filing disclosed on April 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Thermo Fisher Scientific stock on March 27th. The trade occurred in the Representative’s “SARAH LANDSMAN TRADITIONAL IRA” account.

Representative Greg Landsman also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of CrowdStrike (NASDAQ:CRWD) on 3/27/2025.
• Sold $1,001 – $15,000 in shares of Cadence Design Systems (NASDAQ:CDNS) on 3/27/2025.
• Sold $15,001 – $50,000 in shares of Simon Property Group (NYSE:SPG) on 3/27/2025.
• Sold $1,001 – $15,000 in shares of L3Harris Technologies (NYSE:LHX) on 3/27/2025.
• Sold $15,001 – $50,000 in shares of Visa (NYSE:V) on 3/27/2025.
• Sold $15,001 – $50,000 in shares of Cencora (NYSE:COR) on 3/27/2025.
• Sold $15,001 – $50,000 in shares of Alphabet (NASDAQ:GOOGL) on 3/27/2025.
• Sold $1,001 – $15,000 in shares of Ameriprise Financial (NYSE:AMP) on 3/27/2025.
• Sold $15,001 – $50,000 in shares of Salesforce (NYSE:CRM) on 3/27/2025.
• Sold $1,001 – $15,000 in shares of Equinix (NASDAQ:EQIX) on 3/27/2025.

Thermo Fisher Scientific Stock Down 6.1 %

Shares of NYSE TMO traded down $27.52 during midday trading on Thursday, hitting $426.03. 618,116 shares of the stock traded hands, compared to its average volume of 1,677,410. Thermo Fisher Scientific Inc. has a one year low of $409.85 and a one year high of $627.88. The business has a 50 day moving average price of $516.75 and a two-hundred day moving average price of $541.75. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The company has a market cap of $160.72 billion, a PE ratio of 26.03, a P/E/G ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be paid a dividend of $0.43 per share. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date of this dividend is Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is 10.41%.

Insider Transactions at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the sale, the senior vice president now owns 10,816 shares of the company’s stock, valued at approximately $5,759,736.32. This represents a 25.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the sale, the executive vice president now directly owns 16,363 shares of the company’s stock, valued at $9,582,009.17. The trade was a 1.80 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,900 shares of company stock worth $13,106,062. Company insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Wells Fargo & Company boosted their price objective on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. Morgan Stanley increased their price target on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. UBS Group increased their target price on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a research report on Friday, January 31st. Finally, Royal Bank of Canada set a $693.00 price objective on Thermo Fisher Scientific in a research note on Friday, January 31st. Four investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $653.23.

Institutional Trading of Thermo Fisher Scientific

A number of hedge funds have recently made changes to their positions in TMO. Norges Bank purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at about $3,149,754,000. GAMMA Investing LLC lifted its holdings in shares of Thermo Fisher Scientific by 60,610.9% in the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company’s stock worth $1,203,859,000 after acquiring an additional 2,415,346 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in shares of Thermo Fisher Scientific by 86.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company’s stock valued at $1,604,338,000 after purchasing an additional 1,433,444 shares during the last quarter. Kovitz Investment Group Partners LLC lifted its stake in Thermo Fisher Scientific by 1,905.4% in the fourth quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company’s stock worth $469,889,000 after purchasing an additional 858,193 shares during the last quarter. Finally, Proficio Capital Partners LLC boosted its position in Thermo Fisher Scientific by 68,617.0% during the fourth quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company’s stock valued at $396,810,000 after buying an additional 761,649 shares during the period. 89.23% of the stock is owned by institutional investors.

About Representative Landsman

Greg Landsman (Democratic Party) is a member of the U.S. House, representing Ohio’s 1st Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Landsman (Democratic Party) is running for re-election to the U.S. House to represent Ohio’s 1st Congressional District. He declared candidacy for the 2026 election.

Greg Landsman was born in Cincinnati, Ohio, and lives in Mt. Washington, Ohio. Landsman earned a B.A. in economics and political science from Ohio University and an M.A. in theological studies, religion, and public policy from Harvard University in 2004. His career experience includes working as the executive director of The Strive Partnership with the KnowledgeWorks Foundation and the director of the Ohio Governor’s Office of Faith-Based and Community Initiatives.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.